- Health Canada DPD: APO-PERINDOPRIL/AMLODIPINE (APOTEX INC, DIN 02468581) · product monograph (PDF)
- Health Canada DPD: PMS-PERINDOPRIL-AMLODIPINE (PHARMASCIENCE INC, DIN 02541696) · product monograph (PDF)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Hypertension US FDA label
Kidney dosing: Amlodipine (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing: 5 mg once daily, maximum 10 mg (label).
- eGFR 30–59
- No adjustment (label).
- eGFR 15–29
- No adjustment (label).
- eGFR <15 (not on dialysis)
- Usual initial dose (label: patients with renal failure).
- Hemodialysis (intermittent)
- No adjustment; hemodialysis is unlikely to remove amlodipine (label, Overdosage).
- Peritoneal dialysis
- No label adjustment; no PD data (amlodipine is hepatically cleared and not dialyzed).
- CRRT
- No data in label.
- Dialyzable? No: highly protein bound; hemodialysis not likely to help (label).
- Monitoring Blood pressure, edema. Lower starting dose (2.5 mg) in older adults and hepatic impairment (label).
From the Amlodipine monograph (renalcarematters.com, reviewed).
Use: Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Contraindications
- History of ACE-inhibitor angioedema; hereditary or idiopathic angioedema
- Second and third trimesters of pregnancy
- Significant bilateral renal artery stenosis or stenosis to a single functioning kidney
- Aliskiren with diabetes or GFR <60 mL/min/1.73 m2
- Sacubitril/valsartan within 36 hours
- Extracorporeal treatments using negatively charged surfaces (some high-flux membranes, LDL apheresis)
- Severe hypotension, shock, left ventricular outflow obstruction
- Hemodynamically unstable heart failure after acute myocardial infarction
- Hypersensitivity to perindopril, other ACE inhibitors or dihydropyridines
Dosing: Adult
- Hypertension or stable coronary artery disease, substitution for the separate drugs: One tablet once daily in the morning before a meal, at the same perindopril and amlodipine doses the patient already takes
Dosing: Altered kidney function
The fixed combination is a substitution product for patients already controlled on the same doses given separately. Perindoprilat, the active ACE-inhibitor metabolite, is cleared by the kidneys and accumulates in kidney impairment, whereas amlodipine needs no kidney adjustment. The European label allows the combination only at creatinine clearance (CrCl) 60 mL/min or above; below that, the components are titrated separately. It has no US FDA label.
Kidney function measure: European summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min).
Show full dosing details
- CrCl ≥60 mL/min
- One tablet once daily in the morning before a meal, at the strengths the patient already takes as separate drugs (SmPC). Monitor potassium and creatinine.
- CrCl 30–59 mL/min
- Not suitable at CrCl <60 mL/min: titrate perindopril and amlodipine separately (SmPC). Perindoprilat accumulates as kidney function falls.
- CrCl 15–29 mL/min
- Not suitable at CrCl <60 mL/min: titrate perindopril and amlodipine separately (SmPC). Perindoprilat accumulates as kidney function falls.
- CrCl <15 mL/min (not on dialysis)
- Not suitable at CrCl <60 mL/min: titrate perindopril and amlodipine separately (SmPC). Perindoprilat accumulates as kidney function falls.
- Hemodialysis (intermittent)
- Not suitable (CrCl <60). Perindoprilat is dialyzable (dialysis clearance 70 mL/min); amlodipine is not. Use the separate drugs. Avoid high-flux polyacrylonitrile (AN69) membranes with ACE inhibitors (anaphylactoid reactions) (SmPC 4.3, 4.4).
- Peritoneal dialysis
- Not suitable (CrCl <60); use the separate drugs.
- CRRT
- Not suitable; use separate drugs if needed. Extracorporeal circuits with negatively charged surfaces are contraindicated with ACE inhibitors (SmPC 4.3).
- Dialyzable? Perindoprilat: yes (dialysis clearance 70 mL/min). Amlodipine: no (about 97.5% protein-bound) (SmPC).
- Monitoring Potassium and creatinine routinely in CKD; blood pressure, kidney function and potassium closely in patients at risk of hypotension or with renal artery stenosis. Hyperkalemia risk higher with CKD, age over 70, diabetes, potassium-sparing diuretics, potassium supplements or salt substitutes (SmPC 4.4).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (August 2022). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established in children (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Tablet: 3.5 mg/2.5 mg, 5 mg/10 mg, 5 mg/5 mg, 7 mg/5 mg, 10 mg/10 mg, 10 mg/5 mg
Registered products in the Philippines
10 products registered with the Food and Drug Administration (FDA) Philippines list Amlodipine + Perindopril as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products10
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AmloperiPerindopril (as arginine) + Amlodipine (as besilate) | 10 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17664 | Mar 12, 2032 | |
AmloperiPerindopril (As Arginine) + Amlodipine (As Besilate) | 3.5mg/2.5mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises, Inc. | DRP-18360 | Jun 23, 2032 | |
AmloperiPerindopril (as arginine) + Amlodipine (as besilate) | 5 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17666 | Mar 12, 2032 | |
AmloperiPerindopril (as arginine) + Amlodipine (as besilate) | 7 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17665 | Mar 12, 2032 | |
CoveramPerindopril (as arginine) + Amlodipine (as besilate) | 10 mg/ 5 mg TabletPolypropylene Bottle x 30's (Box of 1's) | RxVAT-exempt | Servier (Ireland) Industries Ltd.Ireland | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY36011 | Jun 22, 2029 | |
CoveramPerindopril (as arginine) + Amlodipine (as besilate) | 10 mg/10 mg TabletPolypropylene Bottle x 30's Box of 1's | RxVAT-exempt | Servier (Ireland) Industries Ltd.Ireland | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY36012 | Jun 22, 2029 | |
CoveramPerindopril (as arginine) + Amlodipine (as besilate) | 5 mg/ 10 mg TabletPolypropylene Bottle x 30's Box of 1's | RxVAT-exempt | Servier (Ireland) Industries Ltd.Ireland | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY36010 | Jun 22, 2029 | |
CoveramPerindopril (as arginine) + Amlodipine (as besilate) | 5 mg/5 mg TabletPolypropylene Bottle x 30's Box of 1's | RxVAT-exempt | Servier (Ireland) Industries Ltd.Ireland | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY36009 | Jun 22, 2029 | |
ViacoramPerindopril (as arginine) + Amlodipine (as besilate) | 7 mg/ 5mg TabletPolypropylene container x 30's (Box of 1's) | RxVAT-exempt | Servier (Ireland) Industries, Ltd.Ireland | Zuellig Pharma CorporationImporter: Servier Philippines, Inc.Trader: Les Laboratoires Servier | DR-XY45453 | Jun 20, 2031 | |
Viacoram InitioPerindopril (as arginine) + Amlodipine (as besilate) | 3.5 mg/ 2.5 mg TabletPolypropylene container x 30's (Box of 1's) | RxVAT-exempt | Servier (Ireland) Industries, Ltd.Ireland | Zuellig Pharma CorporationImporter: Servier Philippines, Inc.Trader: Les Laboratories Servier | DR-XY45452 | Jun 20, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Aliskiren | Avoid | Hyperkalemia, kidney impairment, hypotension. | Contraindicated with diabetes or GFR <60; otherwise not recommended. |
| Sacubitril/valsartan | Avoid | Angioedema. | Contraindicated; separate by 36 hours. |
| ARBs (dual RAAS blockade) | Avoid | Hyperkalemia, acute kidney injury, hypotension. | Not recommended; specialist only with close monitoring. |
| Potassium-sparing diuretics, potassium supplements, salt substitutes | Adjust or monitor | Hyperkalemia. | Not recommended; if needed, monitor potassium frequently. |
| NSAIDs | Adjust or monitor | Less blood-pressure control; kidney injury and hyperkalemia. | Hydrate; monitor kidney function. |
| Lithium | Adjust or monitor | Lithium toxicity. | Not recommended; monitor lithium levels if needed. |
| Strong or moderate CYP3A4 inhibitors; tacrolimus, cyclosporine; simvastatin | Adjust or monitor | Higher amlodipine exposure; amlodipine raises tacrolimus and cyclosporine levels and simvastatin exposure. | Monitor; check immunosuppressant levels; limit simvastatin to 20 mg/day. |
| Racecadotril, mTOR inhibitors, gliptins | Adjust or monitor | Higher angioedema risk. | Caution when starting. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Edema (amlodipine)
- Cough (perindopril)
- Dizziness, headache, hypotension
- Palpitations, flushing
- Gastrointestinal upset
Serious
- Angioedema
- Hyperkalemia
- Acute kidney injury (especially with renal artery stenosis, volume depletion, NSAIDs)
- Agranulocytosis, thrombocytopenia (very rare)
Monitoring parameters
- Potassium and creatinine routinely in CKD; blood pressure, kidney function and potassium closely in patients at risk of hypotension or with renal artery stenosis. Hyperkalemia risk higher with CKD, age over 70, diabetes, potassium-sparing diuretics, potassium supplements or salt substitutes (SmPC 4.4). Kidney
- Potassium and creatinine (within 1 to 2 weeks of starting or changing dose, then periodically)
- Blood pressure
- Angioedema symptoms
Pharmacokinetics
Key PK parameters
| Half-life | Perindoprilat about 17 hours (unbound terminal); amlodipine 35 to 50 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Perindoprilat elimination reduced in kidney failure (not quantified); amlodipine unchanged |
| Protein binding | Perindoprilat 20%; amlodipine about 97.5% |
| Metabolism (CYP, transporters) | Perindopril hydrolyzed to active perindoprilat; amlodipine hepatic (CYP3A4) |
| Active metabolites | Perindoprilat |
| Renal excretion kidney | Perindoprilat in urine; amlodipine 10% unchanged and 60% as metabolites in urine |
| Dialyzability kidney | Perindoprilat yes (70 mL/min); amlodipine no |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Acerycal 5 mg/5 mg tablets SmPC (PA0568/018/001) [HPRA (Ireland) product information, August 2022; no US FDA label]. https://assets.hpra.ie/products/Human/18541/Licence_PA0568-018-001_08082022103112.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Les Laboratoires Servier. (2022). Acerycal 5 mg/5 mg tablets (perindopril arginine/amlodipine) [Summary of product characteristics, licence PA0568/018/001; text revised August 2022]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/18541/Licence_PA0568-018-001_08082022103112.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .

